Sector revisions Bolt Biotherapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 20/04/2026 BST			5-day change	1st Jan Change
5.150 ^USD	+8.88%		+10.52%	-5.82%

03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-11	Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
BOLT BIOTHERAPEUTICS, INC.				3
ARGENX SE				15
WUXI APPTEC CO., LTD.				18
INSMED INCORPORATED				20
BIONTECH SE				18
SUMMIT THERAPEUTICS INC.				14
WUXI BIOLOGICS (CAYMAN) INC.				21
AKESO, INC.				21
GENMAB A/S				14
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				17
MADRIGAL PHARMACEUTICALS, INC.				14
EXELIXIS, INC.				18
REMEGEN CO., LTD.				15
SAMSUNG EPIS HOLDINGS CO., LTD.	-	-	-	1
ARROWHEAD PHARMACEUTICALS, INC.				11
VAXCYTE, INC.				9
NUVALENT, INC.				18
CYTOKINETICS, INCORPORATED				18
IMMUNITYBIO, INC.				5
PHARMAESSENTIA CORPORATION				7
Average				14
Weighted average by Cap.				16